While CD16 and NKG2D are among the first to be used for engaging NK cells, NKp46 is becoming a hot target since NKp46 is more sustainably expressed in tumor-infiltrating NK cells, whereas CD16 and NKG2D are frequently down-regulated [149]. The gene discussed is KLRK1; the disease is neoplasm.